Topic
Antibody-Drug Conjugates (ADCs)
Podcasts
Tumor Board # 86Oct 20, 2026Optimizing Treatment for Advanced HER2-Positive Upper GI Cancers
When a gastroesophageal tumor is positive for HER2, PD-L1, and claudin 18.2, which target should you treat first and how do you decide? On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews Dr. Geoffrey Buckle, a GI medical oncologist at UCSF, and Dr. Ronan Hsieh, a GI oncologist at Swedish Cancer Institute in Seattle, for a breakdown of therapy selection and management in advanced HER2-positive upper GI cancers. They start with a detailed case, covering biomarker workup, how to choose a first-line regimen without head-to-head data, and how to manage nutrition and palliative radiation when a patient presents with dysphagia and weight loss.
- Tumor Board # 84Oct 6, 2026
Managing Refractory MSS-MCRC: Advanced Treatment Strategies
What options remain when a patient with microsatellite stable metastatic colorectal cancer (MSS mCRC) has progressed through every standard line of chemotherapy? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Sandra Algaze to explore the nuances of late-line management in MSS-mCRC. They discuss how to approach oxaliplatin retreatment and anti-EGFR rechallenge, the growing role of liquid biopsy and biomarker-driven selection, and the practicalities of DPYD testing after recent guideline changes.
- Tumor Board # 76Aug 11, 2026
GU Oncology: ASCO Highlights & Impacts on Practice
Is GU oncology entering a new era of early intensification and precision therapy? On this episode of the BackTable Tumor Board Podcast, Dr. Katy Beckermann and Dr. Alan Tan break down the latest GU oncology highlights from ASCO, including key updates in prostate, renal cell, and urothelial carcinoma. They discuss new data supporting HRR/BRCA-focused therapy in HSPC, the importance of early biomarker testing, and ongoing debates about overtreatment and real-world practice impact.
- Tumor Board # 52Mar 24, 2026
Antibody Drug Conjugates Across the HER2 Spectrum: From HER2-Positive to Ultralow Breast Cancer
Antibody-drug conjugates (ADCs) are expanding treatment options in breast cancer, but their use requires careful attention to toxicity. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Sara Nunnery review the role of ADCs in HER2-positive disease and their growing application in HER2-low and HER2-ultralow metastatic settings.
- Tumor Board # 48Feb 17, 2026
HER2-Positive Metastatic Breast Cancer: Treatment Insights & Protocols
In a patient with metastatic HER2-positive breast cancer, what should guide the next decision: trial data, toxicity, or durability of response? In this episode of BackTable Tumor Board, Dr. Lindsay Peterson (Washington University) sits down with Dr. Erica Hamilton (Sarah Cannon Research Institute) to examine how next-generation HER2-directed therapies are reshaping the management of metastatic disease. As treatment options expand beyond trastuzumab-based regimens to agents such as trastuzumab deruxtecan and tucatinib, clinical decision-making increasingly hinges on sequencing strategy, interpretation of evolving trial data, and thoughtful toxicity management.
Urology # 287Jan 30, 2026Urothelial Carcinoma: Understanding ctDNA & Precision Medicine
Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma.
- Tumor Board # 45Jan 27, 2026
Urothelial Carcinoma: Understanding ctDNA & Precision Medicine
Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma.
- Urology # 193Oct 8, 2024
Bladder Cancer Innovations: ESMO 2024 Highlights
Catch up on the latest breakthroughs in bladder cancer management. In this episode of the BackTable Urology Podcast, Dr. Bogdana Schmidt (University of Utah) speaks with Dr. Andrea Apolo, a medical oncologist at the National Cancer Institute, about recent advancements in bladder cancer treatment presented at the 2024 European Society of Medical Oncology (ESMO) Congress.